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Development of a pH Sensor to Probe
Endosomal Buffering of Polymeric Nanoparticles
Effective for Gene Delivery
David R. Wilson1, Denis Routkevitch1, Karl J. Wahlin2, Don J.
Zack2, Alfredo Quinones-Hinojosa3, Jordan J. Green1
1
Biomedical Engineering, Johns Hopkins University, Baltimore,
MD, 2Opthalmology, Johns Hopkins University, Baltimore, MD,
3
Neurosurgery, Johns Hopkins University, Baltimore, MD

Introduction: Polymeric gene delivery suffers from low efficacy
compared to viral gene delivery with one of the primary barriers to
successful transfection being efficient endosomal escape. Cationic
polymers have been hypothesized to facilitate endosomal escape
via the proton sponge mechanism by buffering hydrogen ions in
the endosomal compartment. Here we have created a nucleic acid
based pH sensor and applied it using flow cytometry and confocal
microscopy to investigate endosomal buffering of synthetic
biodegradable cationic polymers for gene delivery, correlating the
pH of delivered DNA with transfection. Methods: We created a
nucleic acid pH sensor by conjugating pH sensitive (FITC, OG) and
insensitive (Cy5) fluorophores to plasmid DNA. The fluorescence
ratio of the sensor was calibrated to pH using flow cytometry and
confocal microscopy following electroporation into cells. Cells were
transfected with the plasmid pH sensor complexed with cationic
polymers including poly(beta-amino ester)s (PBAEs) of variable
transfection efficacy to investigate endosomal buffering. Additionally,
confocal microscopy was used to assess colocalization of the plasmid
pH sensor with a lysosomal dye. Results: PBAEs were demonstrated
to effectively buffer endosomes and avoid lysosomal fate, whereas the
negative controls poly-L-lysine (PLL) and polyethylenimine (PEI)
were shown to accumulate in lysosomes by 24h post-transfection.
The polymer molecular weight and weight-weight ratio to plasmid
DNA was shown to have an effect on endosomal buffering as well as
transfection efficacy in the case of PBAEs. From confocal microscopy
analysis of endosomes, local pH was observed to be higher at the
endosomal membrane than in the center, which may be indicative
of polymer enrichment along the membrane due to excess soluble
polymer. Conclusions: The constructed DNA sensor gave a linear
relationship with intracellular pH. When investigating PBAE-induced
buffering, results were consistent with the hypothesized proton
sponge mechanism. These cationic polymers were demonstrated to
affect endosomal pH and DNA lysosomal fate and lead to successful
transfection.
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Fig 1: Confocal microscopy was used to assess the compartmental
pH of endosomes containing nanoparticles formed with the pH sensor.
Lysosome colocalization is shown in merged thresholded images
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with lysosomes (blue), DNA non-colocalized with lysosomes (pink)
and DNA colocalized with lysosomes (yellow). Scattergrams show
DNA fluorescence (horizontal) and lysosome fluorescence (vertical).
Scale bar 10 µm.
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Fig 2. Confocal microscopy images were analyzed at (A) 1 hour and
(B) 24 hours post-transfection using Pearson’s correlation coefficient
M1 to assess the fraction of DNA colocalized with lysosomal stain.
When delivered via PBAE 447, the fraction of DNA colocalized
with lysosomes was significantly different than both bPEI and PLL
at both time points.
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Receptors After Plasmid Electrotransfer in
Melanoma Cells and Tumors

Loree Heller1, Masa Bosnjak2, Katarina Znidar3, Maja Cemazar2
1
Old Dominion University, Norfolk, VA, 2Institute of Oncology
Ljubljana, Ljubljana, Slovenia, 3University of Primorska, Izola,
Slovenia
In vivo electroporation or electrotransfer, the application of
controlled electric pulses, enhances delivery of plasmid DNA to
a wide variety of healthy tissues as well as many tumor types.
Electrotransfer of pDNA encoding therapeutic genes substantially
increases gene expression, enhancing subsequent therapeutic
effects. Delivery of therapeutic plasmid DNA has reached clinical
trials in the US and in Europe, primarily for cancer therapies and
infectious disease vaccines. In several preclinical tumor models,
delayed tumor growth, increased survival time, and even complete
tumor regression can occur with intratumoral electroporation, also
known as electrotransfer, of DNA oligonucleotides or plasmid DNA
devoid of a therapeutic gene (empty vector). In B16.F10 mouse
melanomas, these effects are preceded by significant elevation of
several proinflammatory cytokines and chemokines including IFNβ,
implicating the binding and activation of intracellular DNA-specific
pattern recognition receptors in response to DNA electrotransfer. The
purpose of this study was to investigate whether melanoma tumors
and cells express cytosolic DNA sensors and whether these sensors
respond to pDNA electrotransfer. Histologically, tumor necrosis
independent of caspase-3 was observed. Although the mRNAs for
several DNA sensors were detected in tumors, none was significantly
upregulated. In B16.F10 cells in culture, IFNβ mRNA and protein
levels were significantly upregulated after pDNA electrotransfer.
The mRNAs for several DNA sensors were present in these cells
and DAI, DDX60, and p204 mRNAs were significantly upregulated
after pDNA electrotransfer. DDX60 protein levels were coordinately
upregulated. Mirroring the observation of tumor necrosis, cells
underwent a significant pDNA concentration-dependent decrease in
proliferation and survival. Taken together, increased IFNβ and DNA
sensor expression accompanied by cell death and tumor necrosis
indicate that pDNA electrotransfer activates intracellular DNA
sensors in B16.F10 cells and tumors, producing both in vitro and in
vivo effects. The absence of activation of DNA sensors in vivo could
be due to the lower transfection efficiency compared to that in vitro
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musculo-skeletAl diseAses
or to dilution by other tumor cell types. Electrotransfer is an efficient
means of enhancing plasmid DNA introduction into tissues such
as skin, muscle, and tumors for therapeutic application. Localized
inflammation and induced cell death may contribute to cancer gene
therapies but may impede gene therapies for which these effects are
not desirable.
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Elucidating Design Rules Governing
Extracellular Vesicle-Mediated Therapeutic Protein
Delivery
Michelle E. Hung, Joshua N. Leonard
Chemical and Biological Engineering, Northwestern University,
Evanston, IL

Extracellular vesicles (EVs) are secreted biological nanoparticles
that have great potential as therapeutic delivery vehicles - they are
well-tolerated in vivo and naturally capable of transferring RNA and
proteins between cells. Our ability to engineer EVs as therapeutic
delivery vehicles is limited by an incomplete understanding of how
EVs load biomolecular cargo and deliver it to recipient cells. In
particular, the biophysical rules governing mRNA and protein delivery
by EVs have not been elucidated. Open questions include: Does size
limit mRNA loading efficiency into EVs? To what extent is EV mRNA
cargo translated in recipient cells? What factors impact the degree
to which RNA and protein cargo are delivered to the cytoplasm of
recipient cells?
To quantitatively investigate the above questions, we leveraged
our Targeted and Modular EV Loading (TAMEL) platform, which
enables active loading of specific cargo RNA into EVs. TAMEL can
enrich cargo mRNA loading into EVs up to 40-fold relative to passive
loading. By directly comparing active loading efficiencies between
mRNAs of different lengths, we characterized what type of RNAs
can be loaded into EVs. While active loading of mRNA-length (>
1.5 kb) cargo molecules was significant, active loading was much
more efficient for smaller (~0.5 kb) RNA molecules, providing the
first direct evidence for the impact of cargo RNA size on loading
into EVs. We next leveraged the TAMEL platform to elucidate the
limiting steps in EV-mediated delivery of mRNA and protein to
prostate cancer cells, as a therapeutically relevant model system. In
this model system, we did not observe translation of EV-delivered
mRNA in recipient cells, indicating this is a limiting step in functional
delivery of EV cargo. In contrast, we observed robust EV-mediated
delivery of dTomato reporter protein, and thus further explored EVs
as therapeutic protein delivery vehicles.
To probe the efficacy of EV-mediated therapeutic protein delivery,
we investigated using EVs to deliver the prodrug converting enzyme
cytosine deaminase fused to uracil phosphoribosyl transferase
(CD-UPRT), which converts the prodrug 5-FC to the toxic 5-FU.
Importantly, CD-UPRT can function without without requiring
endosomal escape because both 5-FC and 5-FU are membrane
permeable. We also explored strategies for EV-mediated delivery of
Cas9 nuclease, which must overcome the EV loading barrier imposed
by its NLS sequence as well as escape the endosome in recipient
cells. To address the loading challenge, we investigated a strategy
for conditional NLS reconstitution to allow enhanced loading of
Cas9 into EVs. We then used Cas9 delivery to assess the degree to
which EV-delivered proteins can escape the endosomal/lysosomal
pathways and traffic to other subcellular locations. Altogether, our
investigations elucidated key design rules and central limiting steps
that may guide the further development and utilization of EVs as
therapeutic biomolecule delivery vehicles.
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Follistatin Gene Therapy Improves Six
Minute Walk Distance in Sporadic Inclusion Body
Myositis (sIBM)
Jerry R. Mendell, Zarife Sahenk, Mark Hogan, Samiah Al-Zaidy,
Kevin Flanigan, Louise R. Rodino-Klapac, Markus McColly,
Kathleen Church, Sarah Lewis, Linda Lowes, Lindsay Alfano,
Katherine Berry, Natalie Miller, Igor Dvorchik, Melissa MooreClingenpeel, Brian K. Kaspar
Gene Therapy, The Research Institute at Nationwide Children’s
Hospital, Columbus, OH

Treatment of sIBM poses many challenges. The cause of
this disease is enigmatic, and although considered to be an
inflammatory myopathy, there is resistance to anti-inflammatory and
immunosuppressive agents. sIBM muscle biopsies show vacuolated
muscle fibers, widespread inflammation, and intracellular amyloid
deposits. Follistatin is a potent inhibitor of the myostatin pathway
and its potential as a therapeutic vehicle is enhanced by a pathway
independent of the activin IIB receptor. We have demonstrated
both safety and efficacy following direct intramuscular injection of
follistatin in the quadriceps muscle in a previously reported gene
therapy trial in Becker muscular dystrophy (Mendell JR, et al Mol
Ther 2015). No off target effects were encountered attributed to the
use of an alternatively spliced follistatin isoform, FS344, also used
in the current sIBM gene therapy trial. Enrollment in the current
gene therapy trial included 6 subjects with either definite or possible
sIBM (Griggs RC, et al. Ann Neurol 1995). Pretreatment MRI’s were
obtained to determine areas of relative muscle sparing/lack of fibrosis.
The intramuscular injections of AAV1.CMV.FS344 to 12 to 14 sites
in the quadriceps muscle delivered 1.2X1012 vg/kg. Injections were
performed with direct ultrasound guidance to target the most normal
appearing muscle bundles, and intramuscular position was confirmed
with simultaneous EMG. A three-patient, single limb, safety trial
preceded the Phase I/IIA trial reported here. During the ongoing gene
therapy trial, a control sIBM group (n=20) was prospectively studied
by performance of the 6MWT with follow up from 9-28 months.
The 6MWT was the primary functional outcome (See table below).
sIBM patients treated with AAV1.CMV.FS344 increased the 6MWT
distance by 46.5m (457 to 503.5, p =0.001). Untreated sIBM controls
lost 38.5m over a similar time period resulting in net difference of
85.0m between groups (p=0.0007). To validate findings and confirm
the lack of selection bias we compared a subgroup of untreated sIBM
controls (n=8), matched for age, gender, and 6MWD at baseline.
Matched controls lost 39m (p=0.0036) in the 6MWD, a virtually
identical loss to the larger control group.
The results of this study demonstrate that sIBM can benefit from
follistatin gene therapy based on improvement in distance walked
in the 6MWT. We did find a hierarchy of response based on muscle
preservation and avoiding gene delivery to areas of fibrosis. In this
study, gene delivery was limited to the quadriceps muscle, but in
future trials more widespread delivery could potentially be more
effective.
Six Minute Walk Distance Pre- and Post-Treatment• (median values (interquartile ranges provided)]
Group

Baseline(m)

Final Compared to
Baseline(m)

Change from
Baseline (m)

Change per
Month (m)

slBM Gene Therapy Pts

457
(431,475)

Improved to 503.5
(443,573)

+46.5
(2,117)

+3.09 (0.39,8.9)

393
(356.5,.45 1.5)

Declined to 354.5
(303.5,4 10.5)

-38.5 (-73,-22)
p :0.0007

-2.3 (-4,-1.1)
P=0.0032

459
(439.5,469)

Declined to 420
(388.5,447.5)

-39.0(-77, -8)
p =0.0036

-2.2 (-4.8,-0.7)
P=0.0118

(n =6)

Untreated sIBM Controls
(n=20)
Matched slBM Controls
forage,gender,
and 6MWD (n =8)

Molecular Therapy Volume 24, Supplement 1, May 2016
Copyright © The American Society of Gene & Cell Therapy

S197

